Correction to: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial (Nature Medicine, (2023), 29, 7, (1782-1792), 10.1038/s41591-023-02427-z)

Deepak L. Bhatt, Harold E. Bays, Michael Miller, James E. Cain, Katarzyna Wasilewska, Nabil S. Andrawis, Teresa Parli, Shibao Feng, Lulu Sterling, Leo Tseng, Cynthia L. Hartsfield, Germaine D. Agollah, Hank Mansbach, ENTRIGUE Principal Investigators

Research output: Contribution to journalComment/Letter to the editorAcademic

Abstract

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-023-02427-z, published online 24 June 2023. In the version of the article initially published, there were errors in Fig. 3d. The panel has now been corrected in the HTML and PDF versions of the article, and the original and revised versions can be seen below as Fig. 1. (Figure presented.) Original and revised Fig. 3d.
Original languageEnglish
Pages (from-to)1788-1789
Number of pages2
JournalNature medicine
Volume30
Issue number6
Early online date2024
DOIs
Publication statusPublished - Jun 2024

Cite this